Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma

Trends in Pharmacological Sciences

Volumn 32, Issue 8, 2011, Pages 463-479

  Favoni, Roberto E ^a,b   Florio, Tullio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMUVATINIB; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DASATINIB; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FENRETINIDE; FLUOROURACIL; FORETINIB; GEFITINIB; GEMCITABINE; HEXAMETHYLENEBISACETAMIDE; IMATINIB; IPILIMUMAB; LAPATINIB; MDX 101; METHOTREXATE; MITOMYCIN C; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PEMETREXED; PLATINUM DERIVATIVE; PRALATREXATE; RALTITREXED; RANPIRNASE; RAPAMYCIN; RIDAFOROLIMUS; ROFECOXIB; SEMAXANIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DECORTICATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LOW DRUG DOSE; LUNG RESECTION; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; CISPLATIN; CLINICAL TRIALS AS TOPIC; GLUTAMATES; GUANINE; HUMANS; MEDICAL ONCOLOGY; MESOTHELIOMA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PALLIATIVE CARE; PLEURAL NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RADIOTHERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79960964710     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.03.011     Document Type: Review

References (152)

1. P. Klemperer, and C.B. Rabin Primary neoplasms of the pleura. A report of five cases Arch. Pathol. 11 1931 385
2. J.C. Wagner Diffuse pleural mesothelioma and asbestos exposure in the Northwestern Cape province Br. J. Indust. Med. 17 1960 260 271
3. H.D. Roach Asbestos: when the dust settles an imaging review of asbestos-related disease Radiographics 22 2002 S167 184
4. M. Carbone The pathogenesis of mesothelioma Semin. Oncol. 29 2002 2 17 (Pubitemid 34163530)
5. J. Peto The European mesothelioma epidemic Br. J. Cancer 79 1999 666 672 (Pubitemid 29046253)
6. C. Bianchi, and T. Bianchi Malignant mesothelioma: global incidence and relationship with asbestos Ind. Health 45 2007 379 387 (Pubitemid 47217199)
7. B. Price, and A. Ware Mesothelioma trends in the United States: an update based on surveillance, epidemiology and end results program data for 1973 through 2003 Am. J. Epidemiol. 159 2004 107 112 (Pubitemid 38082517)
8. M.B. Beasley The 2004 World Health Organization classification of lung tumors Semin. Roentgenol. 40 2005 90 97 (Pubitemid 40417889)
9. H. Yang TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis Proc. Natl. Acad. Sci. U.S.A. 103 2006 10397 10402 (Pubitemid 44051178)
10. M. Musti Cytogenetic and molecular genetic changes in malignant mesothelioma Cancer Genet. Cytogenet. 170 2006 9 15 (Pubitemid 44349011)
11. S. Batra Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma Biochem. Biophys. Res. Comm. 342 2006 1228 1232
12. R.E. Favoni Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation Curr. Cancer Drug Targets 2 2010 176 191
13. A. Destro EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations Lung Cancer 51 2006 207 215 (Pubitemid 43144364)
14. L. Strizzi Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma J. Pathol. 193 2001 468 475 (Pubitemid 32266815)
15. C. Belli Malignant pleural mesothelioma: current treatments and emerging drugs Expert Opin. Emerg. Drugs 14 2009 423 437
16. E. Tolnay Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma J. Cancer Res. Clin. Oncol. 124 1998 291 296 (Pubitemid 28332909)
17. S.M. Wilson mTOR mediates survival signals in malignant mesothelioma grown as tumor fragments spheroids Am. J. Respir. Cell Mol. Biol. 39 2008 576 583
18. J.G. Edwards Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura Br. J. Cancer 88 2003 1553 1559 (Pubitemid 36713781)
19. A.M. Allen Fatal pneumonitis associated with intensity modulated radiation therapy for mesothelioma Int. J. Rad. Oncol. Biol. Phys. 65 2006 640 645 (Pubitemid 43795851)
20. C.Q. Cao A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma J. Thorac. Oncol. 10 2010 1692 1703
21. A.S. Tsao Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma Clin. Lung Cancer 10 2009 36 41
22. P.G. Soresen Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma Cancer Treat. Rep. 69 1985 1431 1432
23. D.M. Mintzer Phase II trial of high-dose cisplatin in patients with malignant mesothelioma Cancer Treat. Rep. 69 1985 711 712 (Pubitemid 15031694)
24. A. Krarup-Hansen, and H.H. Hansen Chemotherapy in malignant mesothelioma: a review Cancer Chemother. Pharmacol. 28 1991 319 330
25. M.K. Samson Randomized comparison of cyclophosphamide, imidazole carboxamide and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study J. Clin. Oncol. 5 1987 86 91 (Pubitemid 17007861)
26. E. Spremulli Chemotherapy of malignant mesothelioma Cancer 40 1977 2038 2045 (Pubitemid 8239686)
27. E.A. Eisenhauer Phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study Invest. New Drugs 6 1988 327 329 (Pubitemid 19010333)
28. N. Tsavaris Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma Lung Cancer 11 1994 299 303 (Pubitemid 24289182)
29. A.P. Chahinian Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B J. Clin. Oncol. 11 1993 1559 1565 (Pubitemid 23228263)
30. C. Boutin Malignant pleural mesothelioma Eur. Respir. J. 12 1998 972 981 (Pubitemid 28491677)
31. A. de Cupis Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines Eur. J. Pharmacol. 25 2003 83 95 (Pubitemid 36929872)
32. C. Palumbo HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells Cancer Chemother. Pharmacol. 54 2004 398 406 (Pubitemid 39462964)
33. T. Mukohara Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma Oncology 68 2005 500 510 (Pubitemid 41160983)
34. D.A. Altomare Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth Oncogene 24 2005 6080 6089 (Pubitemid 43080058)
35. M.L. Hartman Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma J. Thorac. Cardiovasc. Surg. 139 2010 1233 1240
36. P. Bertino Preliminary data suggestive of a novel translational approach to mesothelioma therapy: imatinib mesylate with gemcitabine or pemetrexed Thorax 62 2007 690 695 (Pubitemid 47235011)
37. Q. Li The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice Clin. Cancer Res. 13 2007 5918 5925 (Pubitemid 47583920)
38. G.J. Gordon Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma Cancer Chemother. Pharmacol. 61 2008 549 558
39. S. Nagai Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines Chemotherapy 54 2008 166 175 (Pubitemid 351929266)
40. P. Bertino Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts Clin. Cancer. Res. 14 2008 541 548 (Pubitemid 351226124)
41. S.I. Katz Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma Cancer Biol. Ther. 8 2009 2406 2416
42. S.L. O'Kane COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines Lung Cancer 67 2010 160 165
43. D. Stoppoloni Synergistic effect of gefitinib and rofecoxib in mesothelioma cells Mol. Cancer 9 2010 27
44. M.A. Versnel Human malignant mesothelioma cell lines express PDFG-beta receptors whereas cultured normal mesothelioma cells express predominantly PDGF-alpha receptors Oncogene 6 1991 2005 2011 (Pubitemid 21924040)
45. K. Pelin-Enlund Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients Carcinogenesis 11 1990 673 681 (Pubitemid 20137420)
46. A.M. Orengo Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis Eur. Respir. J. 13 1999 527 534 (Pubitemid 29180160)
47. D. Schmitter Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature Int. J. Cancer 51 1992 296 301
48. H.I. Pass Characteristics of nine newly derived mesothelioma cell lines Ann. Thorac. Surg. 59 1995 835 844
49. N. Usami Establishment and characterization of four malignant pleural mesothelioma cell lines Cancer Sci. 97 2006 387 394
50. M.H. Tomasson Cancer stem cells: a guide for skeptics J. Cell Biochem. 106 2009 745 749
51. R.W. Cho, and M.F. Clarke Recent advances in cancer stem cells Curr. Opin. Genet. Dev. 18 2008 48 53 (Pubitemid 351694448)
52. L. Cortes-Dericks Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed Int. J. Oncol. 37 2010 437 444
53. J.E. Visvader Cells of origin in cancer Nature 469 2011 314 322
54. F. Griffero Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors J. Biol. Chem. 284 2009 7138 7148
55. N.Y. Frank The therapeutic promise of the cancer stem cell concept J. Clin. Invest. 120 2010 41 50
56. F.I. Ghani Identification of cancer stem cell markers in human malignant mesothelioma cells Biochem. Biophys. Res. Comm. 404 2011 735 742
57. A. Melotti In vitro and in vivo characterization of highly purified human mesothelioma derived cells BMC Cancer 10 2010 54
58. J.S. Ross Targeted therapy in breast cancer: the HER/2neu gene and protein Mol. Cell Proteomics 3 2004 379 398 (Pubitemid 38702091)
59. G. Giaccone Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer J. Clin. Oncol. 23 2005 3235 3242 (Pubitemid 46211348)
60. A.J. Ryan, and S.R. Wedge ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity Br. J. Cancer 92 Suppl. I 2005 S6 13
61. H. Richly Results of a phase I trial of sorafenib (BAY43-9006) in combination with doxorubicin in patients with refractory solid tumors Ann. Oncol. 17 2006 866 873
62. P. Zhang Gleevec (STI571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro Mol. Cancer 2 2003 1
63. Taverna, P. et al. (2010) Amuvatinib (MP470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor synergizes with etoposide (VP16) in small cell lung cancer (SCLC) cell lines and xenografts. 22nd EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics", Berlin, Germany 16-19, November 2010, Abs. 171.
64. R. Bianco Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumors sensitive and resistant to anti-EGFR drugs Br. J. Cancer 98 2008 923 930 (Pubitemid 351341618)
65. P.C. Fong Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
66. D.A. Fennel Advances in the systemic therapy of malignant pleural mesothelioma Nat. Clin. Pract. Oncol. 5 2008 136 147
67. G.L. Ceresoli Second-line treatment for malignant pleural mesothelioma Cancer Treat. Rev. 36 2010 24 32
68. T. Karrison Final analysis of a multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma [abstract] J. Clin. Oncol. 25 2007 Abs. 7526
69. De Vincenzo, F. et al. (2008) Re-treatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. In: Proceedings of the IX International Conference of the IMIC (International Mesothelioma Interest Group), Amsterdam (The Netherlands), Abs. 163
70. L.M. Krug A multicenter phase II trial of neo-adjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation for stage I-III malignant pleural mesothelioma (MPM) J. Clin. Oncol. 23 2007 Abs. 7561
71. G. Pasello, and A. Favaretto Molecular targets in malignant pleural mesothelioma treatment Curr. Drug Targets 10 2009 1235 1244
72. J.M. Foster Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma World J. Surg. Oncol. 8 2010 88 97
73. A.K. Nowak Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) J. Clin. Oncol. 26 2008 Abs. 8063
74. T.M. Jahan Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107) Proc. Am. Soc. Clin. Oncol. 24 2006 Abs. 7081
75. L.L. Garland SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma J. Clin. Oncol 27 2009 384S Abs. 7511
76. P.A. Janne Sorafenib in malignant pleural mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group (CALGB 30307). In: 2007 ASCO annual meeting proceedings Part I J. Clin. Oncol. 25 Suppl. 2007 Abs. 7707
77. S. Dubey A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307 J. Thorac. Oncol. 5 2010 1655 1661
78. H. Richly Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors Ann. Oncol. 17 2006 866 873
79. TM) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma: NCT 00597116.
80. D.M. Jackman Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma Cancer 113 2008 808 814
81. P. Baas Thalidomide in patients with malignant pleural mesothelioma Lung Cancer 48 2005 291 296
82. N. Pavlakis Thalidomide alone or in combination with cisplatin/ gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies [abstracts] Lung Cancer 41 Suppl. 2 2003 S11
83. E. Raymond Safety and pharmacokinetics of escalated doses of weekly intravenous infusions of CCI-779, a novel mTOR inhibitor, in patients with cancer J. Clin. Oncol. 22 2004 2336 2347 (Pubitemid 41115390)
84. W.K. Kelly Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J. Clin. Oncol. 23 2005 3923 3931 (Pubitemid 46218695)
85. L.M. Krug Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid Clin. Lung Cancer 7 2006 257 261 (Pubitemid 43280028)
86. S.S. Ramalingam Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma J. Thorac. Oncol. 4 2009 97 101
87. H.J. Lerner Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience Cancer 52 1983 1981 1985 (Pubitemid 14232234)
88. R. Ismail-Khan Malignant pleural mesothelioma: a comprehensive review Cancer Control 13 2006 255 263 (Pubitemid 44600936)
89. A. Ardizzoni Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study Cancer 67 1991 2984 2987
90. M. Pistolesi, and J. Rusthoven Malignant pleural mesothelioma: update, current management and newer therapeutic strategies Chest 126 2004 1318 1329 (Pubitemid 39391267)
91. M. Rock Randomized multicenter phase III study of ranpirnase plus doxorubicin versus doxorubicin in patients with unresectable malignant mesothelioma J. Clin. Oncol. 27 2009 383s (Abs. 7507)
92. P. Baas Caelyx in malignant mesothelioma: a phase II EORTC study Ann. Oncol. 11 2000 697 700
93. Y. Oh Phase II study of intravenous Doxil in malignant pleural mesothelioma Invest. New Drugs 18 2000 243 245 (Pubitemid 30599144)
94. J.P. Steele Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma Ann. Oncol. 12 2001 497 499 (Pubitemid 32472104)
95. M.D. Magri Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study Tumori 77 1991 49 51
96. K. Mattson Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cooperativity Group J. Clin. Oncol. 10 1992 824 828
97. A.S.T. Planting Weekly high-dose cisplatin in malignant pleural mesothelioma Ann. Oncol. 5 1994 373 374 (Pubitemid 24142377)
98. N.J. Vogelzang Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J. Clin. Oncol. 21 2003 2636 2644 (Pubitemid 46606305)
99. J.P. van Meerbeeck A randomized phase III study of cisplatin with or without raltitrexed on patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and National Cancer Institute of Canada J. Clin. Oncol. 23 2005 6881 6889
100. M.J. Byrne Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study J. Clin. Oncol. 17 1999 25 30 (Pubitemid 29022374)
101. Van Haarst, J.W. et al., (2000) Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). Program and abstracts of the 9th World Conference on Lung Cancer, September 11-15, Tokyo, Japan, Abs. 56
102. A. Novak Multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma Br. J. Cancer 87 2002 491 496
103. R. Thodtmann Preliminary results of phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors Semin. Oncol. 26 1999 89 93 (Pubitemid 29218034)
104. ®)-oxaliplatin: a step forward in the struggle against mesothelioma? The Institute Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma Eur. J. Cancer 36 2000 1514 1521 (Pubitemid 30619004)
105. J.M.W. Van Haarst Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma Br. J. Cancer 86 2002 342 345 (Pubitemid 34187648)
106. P. Ellis The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline J. Thorac. Oncol. 1 2006 591 601 (Pubitemid 47181411)
107. A. Santoro Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program J. Thorac. Oncol. 3 2008 756 763
108. J.B. Sorensen Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma Br. J. Cancer 8 2008 44 50 (Pubitemid 351920221)
109. D. Raghavan Phase II trial of carboplatin in the management of malignant mesothelioma J. Clin. Oncol. 8 1990 151 154 (Pubitemid 20032458)
110. A. Hughes Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J. Clin. Oncol. 20 2002 3533 3544
111. S.L. Aversa Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): a phase II study for the GSTPV Ann. Oncol. 9 1998 117
112. G. Hillerdal Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin and gemcitabine; a phase II study J. Thorac. Oncol. 3 2008 1325 1331
113. I. Li Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option? Lung Cancer 64 2009 207 210
114. N. Katirtzoglou Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study Clin. Lung Cancer 11 2010 30 35
115. K. Fizazi Combination of raltitrexd and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study J. Clin. Oncol. 21 2003 349 354 (Pubitemid 46606165)
116. W. Schutte A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma Clin. Lung Cancer 4 2003 294 297
117. J.P. Steele Phase II trial of vinorelbine and oxaliplatin (VO) in malignant pleural mesothelioma (MPM) Proc. Am. Soc. Clin. Oncol. 20 2001 Abs. 1335
118. J.P. Steele Phase II study of vinorelbine in patients with malignant pleural mesothelioma J. Clin. Oncol. 18 2000 3912 3917
119. A. Xanthopoulos Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study J. Occup. Toxicol. 3 2008 34
120. O.P. Solheim High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study Br. J. Cancer 65 1992 956 960
121. 12 as front-line therapy in malignant pleural mesothelioma J. Clin. Oncol. 21 2003 1556 1561 (Pubitemid 46594110)
122. G. Scagliotti Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant mesothelioma Eur. J. Cancer 37 Suppl. 6 2001 20
123. G.R. Simon Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial J. Clin. Oncol. 26 2008 3567 3572
124. J. Jassem Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma J. Clin. Oncol. 26 2008 1698 1704
125. P.A. Janne Phase II trial of pemetrexed and gemcitabine in chemotherapy-naïve malignant pleural mesothelioma J. Clin. Oncol. 26 2008 1465 1471
126. J.B. Sorensen Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment J. Thorac. Oncol. 2 2007 147 152 (Pubitemid 47181344)
127. J. Stebbing The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma Lung Cancer 63 2009 94 97
128. J.D. Cowan Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a SouthWest Oncology Group study Invest. New Drugs 6 1988 247 248
129. G. Martensson A phase II study of vincristine in malignant mesothelioma: a negative report Cancer Chemother. Pharmacol. 24 1989 133 134 (Pubitemid 19142157)
130. J. van Meerbeeck Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group Br. J. Cancer 74 1996 961 963 (Pubitemid 26319333)
131. N.J. Vogelzang High-dose paclitaxel plus G-CFS for malignant mesothelioma: CALGB phase II study 9234 Ann. Oncol. 10 1999 597 600 (Pubitemid 29305440)
132. C.P. Belani Docetaxel for malignant mesothelioma: phase II study of the eastern Cooperative Oncology Group (ECOG 2595) Proc. Am. Soc. Clin. Oncol. 18 1999 474a
133. Vorobiof, D.A. et al. (2000) Taxotere in malignant pleural mesothelioma. A phase II clinical trial. Program and abstracts of the 9th World Conference on Lung Cancer, September 11-15, Tokyo, Japan, Abs. 58
134. D.A. Vorobiof Malignant pleural mesothelioma: a phase II trial with docetaxel Ann. Oncol. 13 2002 412 415 (Pubitemid 34705002)
135. M. Ralli Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study Anticancer Res. 29 2009 3441 3444
136. J.P. van Meerbeeck A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer, Lung Cancer Cooperative Group Cancer 85 1999 2577 2582
137. R) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma Proc. Ann. Meet. Am. Soc. Clin. Oncol. 17 1998 A1784
138. H.L. Kindler Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B Lung Cancer 31 2001 311 317 (Pubitemid 32107026)
139. B. Castagneto Cisplatin and gemcitabine in malignant pleural mesothelioma of the pleura: a phase II study Am. J. Clin. Oncol. 28 2005 223 226 (Pubitemid 40800471)
140. S.R. Kalmadi Gemcitabine and cisplatin in unresectable malignant mesothelioma: a phase II study of the Southwest Oncology Group (SWOG 9810) Lung Cancer 60 2008 259 263 (Pubitemid 351609140)
141. V.J. Harvey Chemotherapy of diffuse malignant mesothelioma: phase II trials of single agent 5-fluorouracil and adriamycin Cancer 54 1984 961 964 (Pubitemid 14069806)
142. N.J. Vogelzang Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B Cancer 79 1997 2237 2242 (Pubitemid 27227390)
143. B.L. Samuels Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Cancer 82 1998 1578 1584 (Pubitemid 28165006)
144. G.L. Ceresoli Phase II clinical trial of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) Ann. Oncol. 19 2008 Abs 334p
145. R. Govindan Gefitinib in patients with malignant mesothelioma: a phase II study by Cancer and Leukemia Group B Clin. Cancer Res. 11 2005 2300 2304 (Pubitemid 40490190)
146. L.L. Garland Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study J. Clin. Oncol. 25 2007 2406 2413 (Pubitemid 46999211)
147. M. Millward Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma Proc. Am. Soc. Clin. Oncol. 22 2003 912
148. J.L. Villano A phase II trial of imatinib mesylate in patients with malignant mesothelioma Proc. Am. Soc. Clin. Oncol. 22 2004 7200
149. A. Mathy Limited efficacy of imatinib mesylate in malignant pleural mesothelioma: a phase II trial Lung Cancer 50 2005 83 86 (Pubitemid 41297473)
150. H.L. Kindler SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study Proc. Am. Soc. Clin. Oncol. 20 2001 Abs 1359
151. P. Taylor Single-agent pemetrexed for chemo and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program J. Thorac. Oncol. 3 2008 761 764
152. P.A. Zucali Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma Cancer 112 2008 1556 1561